CN109789120A - Granular preparation - Google Patents
Granular preparation Download PDFInfo
- Publication number
- CN109789120A CN109789120A CN201880003639.1A CN201880003639A CN109789120A CN 109789120 A CN109789120 A CN 109789120A CN 201880003639 A CN201880003639 A CN 201880003639A CN 109789120 A CN109789120 A CN 109789120A
- Authority
- CN
- China
- Prior art keywords
- leucine
- valine
- granular preparation
- isoleucine
- gelling agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 84
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 46
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims abstract description 45
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract description 45
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims abstract description 45
- 239000004474 valine Substances 0.000 claims abstract description 45
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 44
- 239000003349 gelling agent Substances 0.000 claims abstract description 44
- 229960000310 isoleucine Drugs 0.000 claims abstract description 43
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims abstract description 43
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 239000008187 granular material Substances 0.000 claims abstract description 11
- 238000009472 formulation Methods 0.000 claims abstract 9
- 239000004480 active ingredient Substances 0.000 claims abstract 3
- 239000000843 powder Substances 0.000 claims description 19
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 13
- 239000000796 flavoring agent Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 235000013355 food flavoring agent Nutrition 0.000 claims description 8
- -1 wherein Substances 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 5
- 229940057106 isoleucine / leucine / valine Drugs 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims 1
- 230000037406 food intake Effects 0.000 abstract 1
- 239000002245 particle Substances 0.000 description 37
- 238000000034 method Methods 0.000 description 15
- 230000000694 effects Effects 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 10
- 235000019658 bitter taste Nutrition 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 239000011246 composite particle Substances 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 238000001879 gelation Methods 0.000 description 7
- 239000000654 additive Substances 0.000 description 6
- 230000000996 additive effect Effects 0.000 description 6
- 235000013339 cereals Nutrition 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 238000007922 dissolution test Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 208000003623 Hypoalbuminemia Diseases 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 229940069328 povidone Drugs 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- 235000020985 whole grains Nutrition 0.000 description 3
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 239000007931 coated granule Substances 0.000 description 2
- 235000021004 dietary regimen Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229940085605 saccharin sodium Drugs 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- OCUSNPIJIZCRSZ-ZTZWCFDHSA-N (2s)-2-amino-3-methylbutanoic acid;(2s)-2-amino-4-methylpentanoic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound CC(C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O OCUSNPIJIZCRSZ-ZTZWCFDHSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- BMGWZHWESYHXHC-UHFFFAOYSA-N 2-amino-3-methylpentanoic acid;2-amino-4-methylpentanoic acid Chemical compound CCC(C)C(N)C(O)=O.CC(C)CC(N)C(O)=O BMGWZHWESYHXHC-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 235000004298 Tamarindus indica Nutrition 0.000 description 1
- 240000004584 Tamarindus indica Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000001033 granulometry Methods 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Substances [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明提供服用感得以改善的含有异亮氨酸、亮氨酸及缬氨酸的颗粒制剂。本发明涉及含有异亮氨酸、亮氨酸及缬氨酸作为有效成分的颗粒制剂，所述颗粒制剂含有胶凝剂。
The present invention provides a granular preparation containing isoleucine, leucine and valine with improved ingestion feeling. The present invention relates to a granule formulation containing isoleucine, leucine and valine as active ingredients, the granule formulation containing a gelling agent.
Description
Technical field
The present invention relates to granular preparations.Specifically, the present invention relates to containing isoleucine, leucine and valine
Grain preparation.
Background technique
As the pharmaceuticals containing isoleucine, leucine and valine, efficacy of a drug Wei Te is effectively treated for hepatopathy etc.
(LIVACT) (registered trademark, same as below) composite particles are commercially available.
Contain 4g effective component in 1 packet (4.15g) Li Weite composite particles, is filled although being used to improve diet regimen amount
Divide but still the hypoalbuminemia (non-patent literature 1) of the uncompensated liver cirrhosis patient of hypoalbuminemia occurs.
Existing technical literature
Non-patent literature
Non-patent literature 1: appended document branched-amino acid supplement Japanese Pharmacopoeia isoleucine leucine valine
Grain revision Li Weite (registered trademark) composite particles in April, 2016 (the 17th edition)
Summary of the invention
Problems to be solved by the invention
Li Weite composite particles are the granular preparations containing a large amount of aminoacid ingredients, are derived from therefore it is required that further improving
Residual etc. takes sense in the bitter taste of amino acid, the mouth of particle.
Project to be solved by this invention be provide take that sense is improved containing isoleucine, leucine and figured silk fabrics ammonia
The granular preparation of acid.
Means for solving the problems
Present inventor has made intensive studies, as a result, it has been found that, by containing isoleucine, leucine and valine
Granular preparation in cooperate gelling agent, be able to solve the above subject, so as to complete the present invention.
That is, the present invention is as described below.
(1)
Granular preparation, is the granular preparation for containing isoleucine, leucine and valine as effective component, described
Grain preparation contains gelling agent.
(2)
Granular preparation as described in (1), wherein gelling agent is carboxyl vinyl polymer or polyethylene oxide.
(3)
Granular preparation as described in (1) or (2), wherein gelling agent is the polycyclic of the average molecular weight with 500,000 or more
Oxidative ethane.
(4)
Granular preparation as described in any one of (1)~(3), wherein the granular preparation gelling agent is in powder form
It is added.
(5)
Granular preparation as described in any one of (1)~(4), the granular preparation is for granular preparation total amount
Contain gelling agent for 0.05~2% amount.
(6)
Granular preparation as described in any one of (1)~(5), the granular preparation is with isoleucine/leucine/valine
The weight ratio of=1/1.9~2.2/1.1~1.3 contains isoleucine, leucine and valine.
(7)
Granular preparation as described in any one of (1)~(6), the granular preparation is for granular preparation total amount
Contain isoleucine, leucine and valine for 80% or more amount.
(8)
Granular preparation as described in any one of (1)~(7), also contains binder and/or corrigent.
(9)
Contain the manufacturing method of isoleucine, leucine and valine as the granular preparation of effective component, the manufacture
In method,
Gelling agent is added into the particle containing isoleucine, leucine and valine.
(10)
Manufacturing method as described in (9), wherein add gelling agent in powder form.
Invention effect
The particle containing isoleucine, leucine and valine that sense is improved is taken in accordance with the invention it is possible to provide
Preparation.
Detailed description of the invention
[Fig. 1] indicates the result of the dissolution test of the granular preparation of embodiment 1.
[Fig. 2] indicates the result of the dissolution test of the granular preparation of comparative example 1.
Specific embodiment
Specifically describe the present invention by specific embodiment, but the present invention is not limited to specific embodiment below,
It can carry out various modifications and implement.
Granular preparation of the invention contains isoleucine, leucine and valine as effective component, and contains gelling
Agent.
In granular preparation of the invention, isoleucine, leucine and valine as effective component are as branch ammonia
Base acid and known amino acid.
In the present invention, respectively, D type, L-type can be used, the mixture of any mixing ratio of D type and L-type can be used,
Also DL type can be used.
Isoleucine, leucine and valine respectively can be synthetic, be also possible to fermentation product.
It is preferable to use meet in the 17th revised edition of Japanese Pharmacopoeia (respectively page 483, page 1711~1712, page 1248)
It is recorded as the amino acid of the standard of l-Isoleucine, L-Leu and Valine.
In the present invention, so-called isoleucine, leucine and the valine of containing refers to as effective component by of the invention
When grain preparation is used as pharmaceuticals, contain isoleucine, leucine and valine as the ingredient for playing effect effect.
About effect the effect of containing the pharmaceuticals of isoleucine, leucine and valine as effective component, in Japan,
The effect of Li Weite composite particles as commercial articles, effect was " although improving diet regimen amount sufficiently but still occurring low white
The hypoalbuminemia of the uncompensated liver cirrhosis patient of proteinemia " is known, but just it is of the invention containing isoleucine,
For the effect of granular preparation as effective component of leucine and valine effect, it is not limited to above-mentioned effect effect.
It in the present invention, as effective component, does not interfere containing other compositions, but preferably only contains isoleucine, leucine
And valine.
Granular preparation of the invention by containing isoleucine, leucine and valine as effective component, so as to
As pharmaceutical granular preparation.
In granular preparation of the invention, the content ratio of isoleucine, leucine and valine is not particularly limited, as
Weight ratio, preferably isoleucine/leucine/valine=1/1.9~2.2/1.1~1.3.
The content of isoleucine, leucine and valine can be suitably set, for granular preparation total amount
Quality % meter, as the lower limit value of its content, preferably 80% or more, more preferably 90% or more, further preferably 95%
More than.
The upper limit value of content as isoleucine, leucine and valine, is not particularly limited, isoleucine, bright ammonia
The content of acid and valine is preferably smaller than 100%, and more preferably 99% hereinafter, further preferably 98% hereinafter, further more
Preferably 97% or less.
The content of isoleucine, leucine and valine can be will be to be preferably worth as upper limit value and lower limit value
Range obtained from each value combination that form is recorded.
Granular preparation of the invention contains gelling agent.
In the present invention, so-called gelling agent refers to the preparation additive as the substrate of gelation and containing water.
It as gelling agent, is not particularly limited, such as hydroxypropyl methylcellulose, methylcellulose, hydroxy propyl cellulose can be enumerated
Element, carboxyl vinyl polymer, sodium alginate, carragheen, xanthan gum, tamarind gum, pectin, locust bean gum, gellan gum, agar
And polyethylene oxide etc..
From the viewpoint of gelatinisation ability and gelation speed, preferably carboxyl vinyl polymer and polyethylene oxide,
More preferable polyethylene oxide.
Gelling agent can be used a kind, can also be used in the form of mixture of more than two kinds.
From the viewpoint of the indexs such as gelatinisation ability and gelation speed, the average molecular weight of gelling agent can be according to glue
It coagulates the type of agent and suitably sets.
Gelatinisation ability can be for example, by seeing appearance when gelling agent is dissolved in water with high concentration, low concentration
It examines to confirm.
In addition, gelation speed can by being stirred after making an addition in water and dissolving by gelling agent, time dependent
The situation of gelation is observed to confirm.
As the measurement concentration of gelatinisation ability, such as high concentration (10w/v%) and low concentration (1w/v%) can be enumerated, is made
For the measurement concentration of gelation speed, can enumerate such as 10w/v%.
For polyethylene oxide, as the lower limit value of its average molecular weight, preferably there is 150,000 or more mean molecule
Amount more preferably has 500,000 or more average molecular weight, further preferably has 1,000,000 or more average molecular weight, further
More preferably there is 2,000,000 or more average molecular weight.
The upper limit value of average molecular weight as polyethylene oxide, is not particularly limited, the mean molecule of polyethylene oxide
Amount preferably 10,000,000 is hereinafter, more preferably 5,000,000 or less.
The average molecular weight of polyethylene oxide can be by using as upper limit value and lower limit value and be preferably worth form note
Range obtained from each value combination carried.
In the present invention, the average molecular weight of gelling agent can be the value that product is indicated, can also be by measuring gelling agent
Solution viscosity to being measured in the form of viscosity average molecular weigh.
Gelling agent contained by granular preparation of the invention preferably adds in powder form and exists.
For the powder of the feed particles addition gelling agent containing isoleucine, leucine and valine.By that will be gelled
Agent is added to feed particles in powder form, to be added with the gelling of powder type on the surface of particle as granular preparation
The state of agent exists.
In the case where being added with gelling agent in powder form in granular preparation of the invention, due on the surface of particle
The state of gelling agent added with powder type exists, therefore granular preparation of the invention (is coated with as so-called coated granule
Particle), the granular preparation that is coated with gelling agent in particle surface it is different.
In coated granule, the feed particles containing isoleucine, leucine and valine are coated with using coating solution.
In this case, gelling agent is contained in coating solution.
In granular preparation, gelling agent add in powder form and exist such as can by evaluation using screening be divided
Gelatinisation ability of the powder from obtained from etc. confirms, is not particularly limited.Alternatively, it is also possible to pass through spectrum picture observation etc.
To confirm that gelling agent adds in powder form and exists.
The content of gelling agent is suitably set according to the type of gelling agent, from the viewpoint of gelatinisation ability and gelation speed
Consider, based on the quality % for granular preparation total amount, preferably 0.01~5%, more preferably 0.05~2%, into
One step is preferably 0.05~1%.The content of gelling agent can be 0.1% or more within the above range.
Granular preparation of the invention can contain isoleucine, leucine made of the method known to existing to utilization
And gelling agent is added in the particle of valine to be manufactured.
In the present invention, for isoleucine, leucine and valine, it can use in Japanese Patent No. 3228288
The method of record is carried out by the solid feed amino acid co-grinding as isoleucine, leucine and valine, and to granularity
It adjusts.
Co-grinding using the method that crushes after in advance mixing isoleucine, leucine and valine or
The method crushed while isoleucine, leucine and valine are mixed.
It in the mixing of solid feed amino acid, is not particularly limited, can use the rotation of the container such as container type mixer
The air stirrings type mixers such as transition mixer, fluidized bed type mixer, the stirring for utilizing agitating paddle and stirring the rotation of ribbon
Mixer, the line mixer mixed in powder conveying pipeline or the raw material supply mouth for being set to pulverizer etc. into
Material type mixer.
It in the crushing of solid feed amino acid, is not particularly limited, can use the impacting type such as hammer-mill, needle mill
The fluid-types such as the drum-types such as (high-speed rotary) pulverizer, ball mill (medium-type) pulverizer or aeropulverizer (air-flowing type) crush
Machine.
In the manufacture of particle containing isoleucine, leucine and valine of the invention, it is not particularly limited, Ke Yili
Pelletizer is flattened with such as high-speed stirred pelletizer, fluidized bed pelletizer, planetary stirring machine, dry type, broken pelletizer, is squeezed out
Pelletizer, rotation pelletizer, spray drying granulation machine or coating granulator.
It is preferable to use high-speed stirred pelletizers or extruding granulator to manufacture particle.
It as extruding granulator, is not particularly limited, extruded type pelletizer, disc-type granulating machine, ring before can enumerating for example
Mode pelletizer, barrel type pelletizer (basket granulator), swing pelletizer and cylinder formula granulator (cylinder
Granulator) etc..
When manufacturing particle, it can cooperate and meet the standards such as Japanese Pharmacopoeia or pharmaceuticals additive standard, can be used as curing
The known additive on medicinal way.
It as additive, is not particularly limited, can enumerate for example as binder, lubricant, colorant, plasticizer, table
Face activating agent, sweetener, corrigent, flavoring agent and fragrance etc. and known additive, wherein preferred binder and/or
Corrigent.
Additive can be used a kind, can also be used in the form of mixture of more than two kinds.
It as binder, is not particularly limited, such as methylcellulose, hydroxypropyl cellulose, hypromellose can be enumerated
The starch such as the cellulose derivatives such as element, hypromellose phthalate, cornstarch, wheaten starch, polyethylene pyrrole
Pyrrolidone (povidone), polyvinyl alcohol, acrylate copolymer etc. synthesize the natural polymers such as high score subclass and Arabic gum, gelatin
Class etc..
As corrigent, be not particularly limited, can enumerate for example citric acid, tartaric acid, aspartame, saccharin, saccharin sodium,
Erythritol, xylitol, mannitol and stevioside etc..It also may include in corrigent as sweetener and known add
Add agent.
It as flavoring agent and fragrance, is not particularly limited, such as menthol, lemon extract, generation sugar can be enumerated
(sugarless), sweet taste essence (sugar flavor) and arbusterol etc..
Present invention it is preferred that utilizing Japan Patent for the particle containing isoleucine, leucine and valine
Corrigent and/or flavoring agent are attached to the surface of particle by the method recorded in No. 3405342.
For being attached with the granularity of particle of corrigent and/or flavoring agent, as long as can be in common fluidized bed value
Under easily maintain flow regime, be not particularly limited, usually 100~2000 μm, preferably 200~1700 μm or so.
As for making corrigent and/or flavoring agent be attached to the liquidation device of particle, it is not particularly limited, can enumerates
Such as FREUND CORPORATION drying apparatus " FLOW DRYER ", FREUND CORPORATION fluidized bed are made
Grain coating device " FLOW COATER ", POWREX CORPORATION system " Glatt GPCG ", DALTON CORPORATION system
" Marumerizer " and (strain) chrysanthemum water makes made " Multi Processor " etc..
In the present invention, containing isoleucine, leucine and valine particle (be preferably attached with corrigent and/or
The particle of flavoring agent) in mixing gelling agent.
In the present invention, (corrigent is preferably preferably attached with to the particle containing isoleucine, leucine and valine
And/or the particle of flavoring agent) in add gelling agent in powder form and mixed.
As above-mentioned mixed method, as long as the method that can be substantially evenly mixed, is not particularly limited,
It can enumerate such as having used common container rotating type mixer (such as V-type, the double-deck pyramid type, rotation rocking type), container
The method of the mixers such as fixed mixer (such as ribbon type, circular cone screw type etc.) or airflow stirring type mixer.
Also it can use each preparation of specified amount using the investment such as Subpackaging machine into defined container and mix
Method.
By adding gelling agent in powder form into the particle containing isoleucine, leucine and valine and being mixed
It closes, can obtain with granular preparation existing for the state of the gelling agent added with powder type.
Granular preparation of the invention is formed by the particle added with gelling agent, which is specified in Japanese Pharmacopoeia
Granule (referring to page 11 of the 17th revised edition of Japanese Pharmacopoeia).
In the present invention, the granularity of granular preparation is usually 100~2000 μm, and preferably 200~1700 μm or so.
In the present invention, so-called granularity refers to the average grain diameter of particle, can use and remembers in the 17th revised edition of Japanese Pharmacopoeia
The 2nd method " sieve method " of ordinary test method 3.04 " granulometry " of load is measured (page 95~97).It should be noted that
Also it can use the ordinary test method 6.03 " test method(s) of the granularity of preparation " recorded in the 17th revised edition of Japanese Pharmacopoeia to carry out
It measures (page 135).
Granular preparation of the invention can be the granular preparation obtained using granular preparation manufacturing method of the invention.
For granular preparation of the invention, residual etc. is taken sense and is able in the bitter taste of amino acid, the mouth of particle
Improve.
In the present invention, providing by adding gelling agent in powder form improves containing isoleucine, leucine and figured silk fabrics ammonia
The method of taking sense of the acid as the granular preparation of effective component.As the improvement for taking sense, can enumerate from amino acid
Remaining improvement etc. in the improvement of bitter taste, the mouth of granular preparation.
Embodiment
Hereinafter, specifically describing the present invention based on embodiment, but the present invention is not limited to these embodiments.This field skill
The present invention can be changed to various modes in the case where not departing from present subject matter by art personnel, these changes are also included within this
In the range of invention.
Embodiment 1
Based on formula recorded in table 1, granular preparation is prepared.
Povidone (Kollidon, 90F) is added into the mixture of l-Isoleucine, L-Leu and Valine, is gathered
The aqueous solution of vinyl alcohol (partially saponified matter), tartaric acid and saccharin sodium hydrate, is granulated using stirring granulating machine and is carried out whole
Grain, drying, thus obtain feed particles.
For feed particles extension fragrance, polyethylene oxide (average molecular weight: 500 is added after whole grain in powder form
Ten thousand) granular preparation, is prepared.
Comparative example 1
Based on formula recorded in table 1, granular preparation is prepared.
It operates similarly with example 1, obtains feed particles.
Feed particles are coated with using the aqueous solution of povidone (Kollidon, 90F), then extend fragrance, whole grain is carried out, by
This prepares granular preparation.
[table 1]
Using the granular preparation prepared in embodiment 1 and comparative example 1, to swallow easness, particle residue degree of difficulty, bitter taste
Power as index, implement sensory evaluation.(n=9)
For swallowing easness, two kinds of particles preparation when taking is compared, selection is easier one swallowed
Side.
For particle residue degree of difficulty, two kinds of particles preparation when taking is compared, selection is more difficult in mouth
A remaining side.
For the power of bitter taste, two kinds of particles preparation is compared, selects the weaker side of bitter taste.
As a result it is shown in table 2.
[table 2]
| Assessment item | Comparative example 1 | Embodiment 1 | It is not different |
| Swallow easness | 0 | 9 | 0 |
| Particle residue degree of difficulty | 0 | 9 | 0 |
| The power of bitter taste | 1 | 6 | 2 |
For the formula of Li Weite composite particles is the granular preparation of comparative example 1, the granular preparation of embodiment 1 exists
It is more excellent to swallow easness, particle residue degree of difficulty, bitter taste aspect, it follows that it is to take the granular preparation for feeling excellent.
Using the granular preparation prepared in embodiment 1 and comparative example 1, Japanese Pharmacopoeia the 17th time revision has been used by being based on
The dissolution test of the sheathed submergence of the 2nd liquid of dissolution test in version, stripping property is evaluated (page 141~145, generally
Test method(s) 6.10 " dissolution test method ").
As a result it is shown in Fig. 1 and Fig. 2.
It confirms for the granular preparation of comparative example 1, initial (the 5 minutes values) of the granular preparation of embodiment 1
Stripping property is low, but confirms the stripping property that two kinds of preparations all show substantially 100% after 15 minutes.Think embodiment 1
Granular preparation also shows that drug effect same as Li Weite composite particles.
Embodiment 2~4
Making polyethylene oxide, (average molecular weight: content 5,000,000) is 0.1%, 1% for granular preparation total amount
Or 2%, it in addition to this, operates similarly with example 1, prepares granular preparation.
Embodiment 5~7
Other than using the polyethylene oxide that average molecular weight is 500,000,1,000,000 or 2,000,000, similarly to Example 1
Operation, prepares granular preparation.
Using the granular preparation prepared in Examples 1 to 7, using foreign body sensation, bitter taste, easness is swallowed as index, is implemented
Sensory evaluation.(n=10)
For each index, not feel: 1 point, do not feel substantially: 2 points, slightly feel: 3 minutes, feel: 4 minutes into
Row scoring, finds out average value.As a result it is shown in table 3.
[table 3]
| Assessment item | Embodiment 1 | Embodiment 2 | Embodiment 3 | Embodiment 4 | Embodiment 5 | Embodiment 6 | Embodiment 7 |
| Swallow easness | 2.4 | 2.7 | 3.0 | 2.4 | 2.5 | 2.5 | 3.0 |
| Foreign body sensation | 2.8 | 2.4 | 2.2 | 2.8 | 2.7 | 2.7 | 2.5 |
| Bitter taste | 2.8 | 2.6 | 2.3 | 2.3 | 2.4 | 2.3 | 2.2 |
Industrial availability
The Li Weite composite particles that granular preparation of the invention is considered being equivalent to present agent have improved take
Property, therefore, there is industrial availability as pharmaceutical granular preparation.
Claims (10)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017030368 | 2017-02-21 | ||
| JP2017-030368 | 2017-02-21 | ||
| PCT/JP2018/005990 WO2018155435A1 (en) | 2017-02-21 | 2018-02-20 | Granular preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109789120A true CN109789120A (en) | 2019-05-21 |
Family
ID=63253165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880003639.1A Pending CN109789120A (en) | 2017-02-21 | 2018-02-20 | Granular preparation |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JP7080215B2 (en) |
| KR (1) | KR102555664B1 (en) |
| CN (1) | CN109789120A (en) |
| PH (1) | PH12019500671B1 (en) |
| SG (1) | SG10202109130WA (en) |
| WO (1) | WO2018155435A1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1316899A (en) * | 1998-07-31 | 2001-10-10 | 大塚制药株式会社 | Pharmaceutical composition having improved taste |
| WO2002034255A1 (en) * | 2000-10-26 | 2002-05-02 | Ajinomoto Co., Inc. | Granular drug preparations containing branched amino acids and process for producing the same |
| CN1874759A (en) * | 2003-10-29 | 2006-12-06 | 盐野义制药株式会社 | Process for producing coated preparation having relieved unpleasantness |
| JP2011093879A (en) * | 2009-10-02 | 2011-05-12 | Ajinomoto Co Inc | Granule containing branched-chain amino acid, and method for producing the same |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU752879B2 (en) * | 1997-12-20 | 2002-10-03 | Genencor International, Inc. | Matrix granule |
| TWI503128B (en) * | 2007-07-31 | 2015-10-11 | Ajinomoto Kk | A granule preparation containing an amino acid with excellent taste |
| MY173730A (en) * | 2008-03-11 | 2020-02-18 | Takeda Pharmaceuticals Co | Orally-disintegrating solid preparation |
| JP5360368B2 (en) * | 2008-09-05 | 2013-12-04 | 味の素株式会社 | Amino acid preparation for oral use with improved dosage |
| JP2013014590A (en) * | 2012-08-02 | 2013-01-24 | Otsuka Pharmaceut Co Ltd | Atrophy inhibitor of alimentary canal and kidney |
-
2018
- 2018-02-20 WO PCT/JP2018/005990 patent/WO2018155435A1/en active Application Filing
- 2018-02-20 PH PH1/2019/500671A patent/PH12019500671B1/en unknown
- 2018-02-20 JP JP2019501340A patent/JP7080215B2/en active Active
- 2018-02-20 CN CN201880003639.1A patent/CN109789120A/en active Pending
- 2018-02-20 KR KR1020197007437A patent/KR102555664B1/en active IP Right Grant
- 2018-02-20 SG SG10202109130WA patent/SG10202109130WA/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1316899A (en) * | 1998-07-31 | 2001-10-10 | 大塚制药株式会社 | Pharmaceutical composition having improved taste |
| WO2002034255A1 (en) * | 2000-10-26 | 2002-05-02 | Ajinomoto Co., Inc. | Granular drug preparations containing branched amino acids and process for producing the same |
| CN1874759A (en) * | 2003-10-29 | 2006-12-06 | 盐野义制药株式会社 | Process for producing coated preparation having relieved unpleasantness |
| JP2011093879A (en) * | 2009-10-02 | 2011-05-12 | Ajinomoto Co Inc | Granule containing branched-chain amino acid, and method for producing the same |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018155435A1 (en) | 2018-08-30 |
| JP7080215B2 (en) | 2022-06-03 |
| PH12019500671A1 (en) | 2019-07-24 |
| SG10202109130WA (en) | 2021-09-29 |
| KR20190117469A (en) | 2019-10-16 |
| JPWO2018155435A1 (en) | 2019-12-12 |
| PH12019500671B1 (en) | 2024-02-02 |
| KR102555664B1 (en) | 2023-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100465214C (en) | Cellulose Powder | |
| JP5439366B2 (en) | Cellulose powder excellent in segregation preventing effect and composition thereof | |
| CN115581671A (en) | Formulations comprising particles | |
| TWI572360B (en) | Tiny cellulose powder | |
| TW200800303A (en) | Composition with sustained release of the active ingredient, process for the preparation thereof and use thereof | |
| KR101377313B1 (en) | Bottled beverage comprising cap containing dietary supplement and bottle filled with dispersion medium for dietary supplement | |
| RU2690672C2 (en) | Method of inducing satiety | |
| JP6998210B2 (en) | Particle composition for easy-to-take solid preparation and easy-to-take solid preparation containing the particle composition | |
| CN106420629B (en) | Branched-amino acid supplement and its preparation method and application | |
| TWI729476B (en) | Cellulose powder, its use and lozenges | |
| CN102885791A (en) | Method for preparing fexofenadine hydrochloride orally disintegrating tablet | |
| JP5515943B2 (en) | Granules containing branched chain amino acids and method for producing the same | |
| CN109789120A (en) | Granular preparation | |
| CN111936168A (en) | Easily administrable granule and method for producing the same | |
| TW201927340A (en) | Cellulose powder | |
| JP4651345B2 (en) | Method for producing collagen-containing preparation | |
| JP2018083923A (en) | Cellulose dispersion, method for producing cellulose dispersion, molded body composition, molded body, and method for producing molded body composition | |
| JP2007008872A (en) | Method for producing granulated granule and the resultant granulated granule, and solid preparation | |
| TW533082B (en) | Tetrahydrolipstatin containing compositions | |
| WO2024204699A1 (en) | Cellulose powder and molded body | |
| JP2020180083A (en) | Cellulose powders, tablets, and methods for producing tablets | |
| JP2020094023A (en) | Excipient granules, tablet and method for producing tablet | |
| JP2013081470A (en) | Bottled beverage comprising cap containing supplement and bottle filled with dispersion medium for supplement |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40003126 Country of ref document: HK |